# The New Strategy for Pharmacological Treatment in People With Schizophrenia

> **NCT00352339** · PHASE4 · UNKNOWN · sponsor: **Inje University** · enrollment: 90 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Rispridoen and Aripiprazole
- **DRUG:** Risperidne
- **DRUG:** Abilify

## Key facts

- **NCT ID:** NCT00352339
- **Lead sponsor:** Inje University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-08
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2009-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352339, "The New Strategy for Pharmacological Treatment in People With Schizophrenia". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00352339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*